跳至主要内容
临床试验/NCT02724267
NCT02724267已完成不适用

A Randomized Controlled Prospective Study of Targeted Internal Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma.

Eastern Hepatobiliary Surgery Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2012年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
1
主要终点
Overall Survival

研究概览

简要总结

The aim of this study is to evaluate the 131I-chTNT-1/B treatment effect and safety of individual therapy using randomized controlled study, in order to acquire the evidence of evidence-based medicine and create a new program of targeted internal radiation therapy in advanced HCC patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Via clinical diagnosis and confirm it is advanced hepatocellular carcinoma
  • •mRECIST estimation: necrosis region in HCC
  • •Negative iodine allergy test
  • •Liver function :Child-Pugh A/B

排除标准

  • •reject to attend;
  • •impossible to come to our hospital for physical examination regularly.
  • •Blood clotting function hindrance; 4, Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer.

研究组 & 干预措施

transcatheter arterial chemoembolization

Active Comparator

Patients will be treated with TACE only.

干预措施: 131I-chTNT-1/B (Biological)

internal radiation group

Experimental

Patients will be treated with TACE combined with internal radiation.

干预措施: 131I-chTNT-1/B (Biological)

结局指标

主要结局

Overall Survival

时间窗: 3 years

次要结局

  • Time to Progression(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ShenFeng

vice president of the Eastern Hepatobiliary Surgery Hospital

Eastern Hepatobiliary Surgery Hospital

研究点 (1)

Loading locations...

相似试验